AGEN Agenus Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AGEN

Price (delayed)

$5.3

Market cap

$111.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$13.8

Enterprise value

$112.92M

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the ...

Highlights
The gross profit has soared by 75% YoY and by 70% from the previous quarter
Agenus's revenue has soared by 59% YoY and by 55% from the previous quarter
AGEN's net income is down by 12% YoY but it is up by 9% QoQ
AGEN's equity has shrunk by 162% YoY and by 24% QoQ
The quick ratio has plunged by 62% YoY and by 26% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.agenusbio.com
Peers: NWBO CLDX MRK JNJ

Key stats

What are the main financial stats of AGEN
Market
Shares outstanding
20.95M
Market cap
$111.01M
Enterprise value
$112.92M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.72
Earnings
Revenue
$156.31M
EBIT
-$147.84M
EBITDA
-$134.25M
Free cash flow
-$230.79M
Per share
EPS
-$13.8
Free cash flow per share
-$12.9
Book value per share
-$8.41
Revenue per share
$8.74
TBVPS
$15.91
Balance sheet
Total assets
$313.91M
Total liabilities
$462.3M
Debt
$78.01M
Equity
-$160.33M
Working capital
-$143.48M
Liquidity
Debt to equity
-0.49
Current ratio
0.44
Quick ratio
0.4
Net debt/EBITDA
-0.01
Margins
EBITDA margin
-85.9%
Gross margin
98%
Net margin
-157.2%
Operating margin
-102.4%
Efficiency
Return on assets
-68.1%
Return on equity
N/A
Return on invested capital
-197.3%
Return on capital employed
-254.8%
Return on sales
-94.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGEN stock price

How has the Agenus stock price performed over time
Intraday
6.64%
1 week
-34.97%
1 month
-52.9%
1 year
194.44%
YTD
-67.99%
QTD
-54.31%

Financial performance

How have Agenus's revenue and profit performed over time
Revenue
$156.31M
Gross profit
$153.2M
Operating income
-$160.11M
Net income
-$245.76M
Gross margin
98%
Net margin
-157.2%
The gross profit has soared by 75% YoY and by 70% from the previous quarter
Agenus's revenue has soared by 59% YoY and by 55% from the previous quarter
AGEN's operating margin has soared by 52% from the previous quarter and by 44% YoY
Agenus's net margin has increased by 41% QoQ and by 30% YoY

Growth

What is Agenus's growth rate over time

Valuation

What is Agenus stock price valuation
P/E
N/A
P/B
N/A
P/S
0.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.72
The EPS is up by 16% since the previous quarter and by 12% year-on-year
AGEN's equity has shrunk by 162% YoY and by 24% QoQ
The stock's price to sales (P/S) is 89% less than its 5-year quarterly average of 5.3 and 86% less than its last 4 quarters average of 4.2
Agenus's revenue has soared by 59% YoY and by 55% from the previous quarter

Efficiency

How efficient is Agenus business performance
The return on sales has surged by 52% since the previous quarter and by 41% year-on-year
Agenus's return on assets has decreased by 35% YoY but it has increased by 2.9% QoQ
Agenus's ROIC has decreased by 14% YoY but it has increased by 11% from the previous quarter

Dividends

What is AGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGEN.

Financial health

How did Agenus financials performed over time
AGEN's total assets is 32% lower than its total liabilities
The quick ratio has plunged by 62% YoY and by 26% from the previous quarter
Agenus's current ratio has shrunk by 61% YoY and by 30% QoQ
Agenus's debt is 149% higher than its equity
AGEN's equity has shrunk by 162% YoY and by 24% QoQ
The debt to equity has surged by 62% year-on-year and by 20% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.